XpresSpa Group Announces Expansion of Health and Wellness Services Beyond COVID-19 Testing
October 26 2020 - 7:41AM
XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”),
a health and wellness company, announced today it has expanded its
testing services beyond COVID-19, as XpresCheck now offers
additional rapid testing services for other communicable diseases
that include influenza, mononucleosis and group A streptococcus,
supporting the health and wellbeing of airport and airlines
employees and the traveling public. XpresCheck is also now offering
this season’s 2020/21 flu vaccination as well as a quadrivalent
high-dose flu vaccine recommended for seniors.
“We will continue to be on the forefront of
Travel Health and Wellness. This pandemic is prompting people to
change the way they think about their health when traveling, paving
the way for this new industry segment in a post COVID-19 world.
People are more focused on preventative measures and staying safe
when it comes to air travel. There’s a new level of awareness
surrounding individual health, and wanting to ensure people are fit
to travel,” said Doug Satzman, XpresSpa CEO. "XpresCheck is
capitalizing on its existing infrastructure to provide essential
services at airports by leveraging our resources to help in the
fight against COVID-19 and by becoming the first airport
coronavirus testing company. The simple administration of flu
vaccinations paves the way for future COVID-19 vaccinations when
they are approved and readily available in the market.”
Current COVID-19 testing options include a rapid
molecular COVID-19 test, the Polymerase Chain Reaction (PCR) Test,
and the Blood Antibody Test. These services are available to all
airport employees, including airline employees, contractors and
workers, concessionaires and their employees, TSA officers, and
U.S. Customs and Border Protection (CPB) agents, as well as airline
passengers. All insurance plans are accepted outside of network and
all patient information remains private and HIPAA-compliant.
Upon FDA approval of a COVID-19 vaccine and
availability, XpresCheck’s medical staff of state licensed
physicians and nurses hope to be able to administer it to airport
employees and travelers as well in the future.
About XpresSpa Group, Inc.
XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading
global health and wellness holding company. XpresSpa Group’s core
asset, XpresSpa, is a leading airport retailer of spa services and
related health and wellness products, with 50 locations in 25
airports globally. Through its XpresTest, Inc. subsidiary, the
Company also provides COVID-19 screening and testing under its
XpresCheck™ brand at JFK International Airport and Newark Liberty
International Airport. To learn more about XpresSpa Group, visit:
www.XpresSpaGroup.com. To learn more about XpresSpa, visit
www.XpresSpa.com. To learn more about XpresCheck, visit
www.XpresCheck.com.
Forward-Looking StatementsThis
press release may contain "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. These include
statements preceded by, followed by or that otherwise include the
words "believes," "expects," "anticipates," "estimates,"
"projects," "intends," "should," "seeks," "future," "continue," or
the negative of such terms, or other comparable terminology. In
particular, these statements include, without limitation,
statements about our expectations relating to our new XpresCheck™
concept, being able to expand testing to other communicable
diseases as well as administer vaccinations for the seasonal flu,
our positioning to be part of the national rollout of a COVID-19
vaccination when it becomes available (including whether such
vaccination becomes available in the near term or at all), the
degree to which our public testing model assists passengers meet
testing requirements in select states and countries, our ability to
identify and gain access to the latest and best COVID-19 testing
methodologies and equipment, and our ability further expand our
initial sites, including at JFK International Airport and
Newark Liberty International Airport, and our overall ability to
manage the regulatory challenges associated with this business
line. Forward-looking statements relating to expectations about
future results or events are based upon information available to
XpresSpa Group as of today's date and are not guarantees of the
future performance of the company, and actual results may vary
materially from the results and expectations discussed. Additional
information concerning these and other risks is contained in
XpresSpa Group’s most recently filed Annual Report on Form 10-K,
Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K
and other Securities and Exchange Commission filings. All
subsequent written and oral forward-looking statements concerning
XpresSpa Group, or other matters and attributable to XpresSpa Group
or any person acting on its behalf are expressly qualified in their
entirety by the cautionary statements above. XpresSpa Group does
not undertake any obligation to publicly update any of these
forward-looking statements to reflect events or circumstances that
may arise after the date hereof.
Media:Julie
FergusonJulie@jfprmedia.com (312) 385-0098
XpresSpa (NASDAQ:XSPA)
Historical Stock Chart
From Apr 2024 to May 2024
XpresSpa (NASDAQ:XSPA)
Historical Stock Chart
From May 2023 to May 2024